Last reviewed · How we verify

somatostatin infusion

Hospices Civils de Lyon · Phase 3 active Small molecule

somatostatin infusion is a Peptide hormone Small molecule drug developed by Hospices Civils de Lyon. It is currently in Phase 3 development for Acute variceal bleeding (esophageal or gastric varices), Gastrointestinal hemorrhage control.

Somatostatin infusion activates somatostatin receptors on neuroendocrine and immune cells to inhibit hormone and cytokine secretion and reduce splanchnic blood flow.

Somatostatin infusion activates somatostatin receptors on neuroendocrine and immune cells to inhibit hormone and cytokine secretion and reduce splanchnic blood flow. Used for Acute variceal bleeding (esophageal or gastric varices), Gastrointestinal hemorrhage control.

At a glance

Generic namesomatostatin infusion
SponsorHospices Civils de Lyon
Drug classPeptide hormone
TargetSomatostatin receptors (SSTR1, SSTR2, SSTR3, SSTR4, SSTR5)
ModalitySmall molecule
Therapeutic areaGastroenterology
PhasePhase 3

Mechanism of action

Somatostatin is a naturally occurring inhibitory peptide hormone that binds to somatostatin receptors (SSTR1-5) distributed across the gastrointestinal tract, pancreas, and immune system. When infused intravenously, it suppresses the release of various hormones (gastrin, secretin, motilin) and reduces mesenteric blood flow, thereby decreasing gastrointestinal secretions and motility. This mechanism is therapeutically exploited in acute variceal bleeding and other conditions involving excessive gastrointestinal hormone secretion.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about somatostatin infusion

What is somatostatin infusion?

somatostatin infusion is a Peptide hormone drug developed by Hospices Civils de Lyon, indicated for Acute variceal bleeding (esophageal or gastric varices), Gastrointestinal hemorrhage control.

How does somatostatin infusion work?

Somatostatin infusion activates somatostatin receptors on neuroendocrine and immune cells to inhibit hormone and cytokine secretion and reduce splanchnic blood flow.

What is somatostatin infusion used for?

somatostatin infusion is indicated for Acute variceal bleeding (esophageal or gastric varices), Gastrointestinal hemorrhage control.

Who makes somatostatin infusion?

somatostatin infusion is developed by Hospices Civils de Lyon (see full Hospices Civils de Lyon pipeline at /company/hospices-civils-de-lyon).

What drug class is somatostatin infusion in?

somatostatin infusion belongs to the Peptide hormone class. See all Peptide hormone drugs at /class/peptide-hormone.

What development phase is somatostatin infusion in?

somatostatin infusion is in Phase 3.

What are the side effects of somatostatin infusion?

Common side effects of somatostatin infusion include Hyperglycemia, Abdominal pain, Diarrhea, Nausea, Injection site reactions.

What does somatostatin infusion target?

somatostatin infusion targets Somatostatin receptors (SSTR1, SSTR2, SSTR3, SSTR4, SSTR5) and is a Peptide hormone.

Related